Literature DB >> 21416127

Kidney transplantation in highly sensitized patients: are there options to overcome a positive crossmatch?

Christian Morath1, Jan Schmidt, Gerhard Opelz, Martin Zeier, Caner Süsal.   

Abstract

Presensitization against a broad array of human leukocyte antigens (HLA) is associated with prolonged waiting times and inferior graft survival in kidney transplantation. Since the late 1960s, a positive lymphocytotoxic crossmatch has been considered a contraindication for kidney transplantation and solutions, such as enrollment of eligible patients in the Acceptable Mismatch Program of Eurotransplant and kidney paired donation in the case of living donor kidney transplantation, have been proposed to avoid this barrier. Alternatively, a positive crossmatch might not be considered as a contraindication for kidney transplantation and one can try to overcome this hurdle by desensitization. In principle, there are three different ways to overcome the crossmatch barrier by desensitization. The highly sensitized patient awaiting a cadaveric kidney transplant may be desensitized either immediately pretransplant when an organ is offered or in advance, during the time on the waiting list, to increase his chance of having a negative crossmatch at the time of transplantation. In the case of living donor kidney transplantation, the patient can be desensitized for days to weeks until the positive crossmatch with his intended living kidney donor becomes negative. "Heidelberg algorithm" is a combination of different measures, such as pretransplant risk estimation, good HLA match, inclusion of patients in the Eurotransplant Acceptable Mismatch program, and desensitization, which leads to timely transplantation and excellent survival rates in highly sensitized patients at a low rate of toxicity. We believe that all available options should be utilized in an integrated manner for the transplantation of kidney transplant recipients who are at a high risk of antibody-mediated rejection.

Entities:  

Mesh:

Year:  2011        PMID: 21416127     DOI: 10.1007/s00423-011-0759-x

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  39 in total

1.  Almost all patients who are waiting for a regraft of a kidney transplant have anti-HLA antibodies.

Authors:  N El-Awar; P Terasaki; V Lazda; A Nikaein; C Manning; A N Arnold
Journal:  Transplant Proc       Date:  2002-11       Impact factor: 1.066

2.  Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients.

Authors:  Nancy L Reinsmoen; Chih-Hung Lai; Harald Heidecke; Mark Haas; Kai Cao; Geraldine Ong; Mehrnoush Naim; Qi Wang; James Mirocha; Joseph Kahwaji; Ashley A Vo; Stanley C Jordan; Duska Dragun
Journal:  Transplantation       Date:  2010-12-27       Impact factor: 4.939

3.  Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies.

Authors:  Gerhard Opelz
Journal:  Lancet       Date:  2005 Apr 30-May 6       Impact factor: 79.321

4.  Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis.

Authors:  J H Yeh; H C Chiu
Journal:  J Neurol       Date:  2000-07       Impact factor: 4.849

5.  Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.

Authors:  Stanley C Jordan; Dolly Tyan; Don Stablein; Matthew McIntosh; Steve Rose; Ashley Vo; Mieko Toyoda; Connie Davis; Ron Shapiro; Deborah Adey; Dawn Milliner; Ralph Graff; Robert Steiner; Gaetano Ciancio; Shobah Sahney; Jimmy Light
Journal:  J Am Soc Nephrol       Date:  2004-12       Impact factor: 10.121

6.  It takes six to boogie: allocating cadaver kidneys in Eurotransplant.

Authors:  Ilias I N Doxiadis; Jacqueline M A Smits; Guido G Persijn; Ulrich Frei; Frans H J Claas
Journal:  Transplantation       Date:  2004-02-27       Impact factor: 4.939

Review 7.  Humoral theory of transplantation.

Authors:  Paul I Terasaki
Journal:  Am J Transplant       Date:  2003-06       Impact factor: 8.086

8.  The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome.

Authors:  Frans H J Claas; Marian D Witvliet; René J Duquesnoy; Guido G Persijn; Ilias I N Doxiadis
Journal:  Transplantation       Date:  2004-07-27       Impact factor: 4.939

9.  Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?

Authors:  Arun Gupta; Victoria Iveson; Mira Varagunam; Stephen Bodger; Paul Sinnott; Raj C Thuraisingham
Journal:  Transplantation       Date:  2008-04-27       Impact factor: 4.939

10.  Rituximab and intravenous immune globulin for desensitization during renal transplantation.

Authors:  Ashley A Vo; Marina Lukovsky; Mieko Toyoda; Jennifer Wang; Nancy L Reinsmoen; Chih-Hung Lai; Alice Peng; Rafael Villicana; Stanley C Jordan
Journal:  N Engl J Med       Date:  2008-07-17       Impact factor: 91.245

View more
  2 in total

Review 1.  Identification and therapeutic management of highly sensitized patients undergoing renal transplantation.

Authors:  Lu Huber; Nils Lachmann; Michael Dürr; Mareen Matz; Lutz Liefeldt; Hans-H Neumayer; Constanze Schönemann; Klemens Budde
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 2.  Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation.

Authors:  Arno Kornberg
Journal:  World J Hepatol       Date:  2015-06-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.